SynbiCITE is a proud sponsor of the ‘Best Emerging UK Synthetic Biology Company’ at the OBN Awards 2017
- Posted on 13 March, 2017
SynbiCITE is pleased to announce once again they will be sponsoring and this year judging the ‘Best Emerging UK Synthetic Biology Company’ at the 9th Annual OBN Awards, 2017. This award recognises the emerging industrial or synthetic biology company that has the most promise. Entrants will be assessed on capital raised, level of innovation and their likely disruptive impact.
In 2016 this prestigious award was won by Touchlight Genetics, a London-based biotechnology company, specialising in enzymatic DNA amplification. In sponsoring this award for another year, SynbiCITE demonstrates their ongoing support of the UK’s burgeoning synthetic biology industry as it continues to grow, diversify and create skilled jobs, a core aim of SynbiCITE.
The finalists this year are:
- Synpromics Ltd: for being the leading developer of synthetic promoters and provider of gene expression solutions to the Biotech industry
- Chain Biotech: for it’s new class of biotherapeutic being transformative and offering more effective and affordable treatment for chronic disease
- Oxford Genetics: for its expertise in designing DNA and using this to optimise the expression of proteins, improving viral delivery systems and cell line engineering
The OBN Awards will take place on Thursday 5th October 2017 at the Oxford Town Hall. The Awards celebrate innovation and outstanding achievement across the UK Life Sciences industry. Categories are broad ranging and include Biotech, Medtech, Synthetic Biology, Digital Healthcare and Investment.
Entries will be assessed by an independent judging panel with three finalists selected to attend the awards.
Full details can be found on the OBN Awards website: www.obn-awards.com
Share this article:
People also read
SynbiTECH 2020 - Register your interest
SynbiTECH will return to London on 6-7th July 2020!To be kept up to date on ticket sales and conference announcements please register your interest he...
Prokarium secures £4.6m Wellcome funding for Entervax
Prokarium has announced an investment of £4.59 million from Wellcome to fund two clinical trials of its lead programme, Entervax.Follow this link for ...
Book before March 29th to receive 20% discount*
Building a multibillion-dollar synthetic biology industry The Synthetic Biology conference taking place in 2019, in London, that is not to be missed....